These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 32395663)

  • 1. A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making.
    Chen X; Hartford A; Zhao J
    Contemp Clin Trials Commun; 2020 Jun; 18():100562. PubMed ID: 32395663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nested combination tests with a time-to-event endpoint using a short-term endpoint for design adaptations.
    Jörgens S; Wassmer G; König F; Posch M
    Pharm Stat; 2019 May; 18(3):329-350. PubMed ID: 30652401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints.
    Uozumi R; Hamada C
    J Biopharm Stat; 2017; 27(1):84-100. PubMed ID: 26881477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
    Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
    Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers.
    Krendyukov A; Singhvi S; Zabransky M
    Front Oncol; 2021; 11():636561. PubMed ID: 33763370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
    Teramukai S; Daimon T; Zohar S
    Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian dose selection design for a binary outcome using restricted response adaptive randomization.
    Meinzer C; Martin R; Suarez JI
    Trials; 2017 Sep; 18(1):420. PubMed ID: 28886745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonparametric adaptive enrichment designs using categorical surrogate data.
    Brückner M; Burger HU; Brannath W
    Stat Med; 2018 Dec; 37(29):4507-4524. PubMed ID: 30191578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.
    Jacob L; Uvarova M; Boulet S; Begaj I; Chevret S
    BMC Med Res Methodol; 2016 Jun; 16():67. PubMed ID: 27250349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive clinical trials of combination treatments.
    Thorlund K; Golchi S; Mills E
    Contemp Clin Trials Commun; 2017 Dec; 8():227-233. PubMed ID: 29696213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.
    Asakura K; Hamasaki T; Evans SR
    Biom J; 2017 Jul; 59(4):703-731. PubMed ID: 27757980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian optimal adaptive designs for delayed-response dose-finding studies.
    Li W; Fu H
    J Biopharm Stat; 2011 Sep; 21(5):888-901. PubMed ID: 21830921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
    Zhou H; Lee JJ; Yuan Y
    Stat Med; 2017 Sep; 36(21):3302-3314. PubMed ID: 28589563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical guide to Bayesian group sequential designs.
    Gsponer T; Gerber F; Bornkamp B; Ohlssen D; Vandemeulebroecke M; Schmidli H
    Pharm Stat; 2014; 13(1):71-80. PubMed ID: 24038922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease.
    Satlin A; Wang J; Logovinsky V; Berry S; Swanson C; Dhadda S; Berry DA
    Alzheimers Dement (N Y); 2016 Jan; 2(1):1-12. PubMed ID: 29067290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive probability of success using surrogate endpoints.
    Saint-Hilary G; Barboux V; Pannaux M; Gasparini M; Robert V; Mastrantonio G
    Stat Med; 2019 May; 38(10):1753-1774. PubMed ID: 30548627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.